Ziv Eizenberg - Allovir Executive Vice President-Human Resources

ALVR
 Stock
  

USD 7.39  0.13  1.73%   

  President
Ms. Ziv Eizenberg is Executive Vice PresidentHuman Resources of Alvarion Ltd. She joined Alvarion in 2008 as HR Director for the Sales Customer Support Division and was later promoted to the position of Executive Vice President of Human Resources. Prior to joining Alvarion Ms. Eizenberg worked at Comverse as a Business Line Human Resources Manager. Before joining Comverse Ms. Eizenberg worked as a consultant for Lotem consultancy firm specializing in organizational development and training
Age: 40  President Since 2012      
617 433 2605  https://www.allovir.com
Eizenberg has a BA in Social Sciences and Consultant Education and an MA Consultant Education from the University of Haifa, Israel.

Allovir Management Efficiency

Allovir has return on total asset (ROA) of (39.1) % which means that it has lost $39.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (70.84) %, meaning that it created substantial loss on money invested by shareholders. Allovir management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 23.13 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Allovir has a current ratio of 10.86, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Allovir until it has trouble settling it off, either with new capital or with free cash flow. So, Allovir's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allovir sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allovir to invest in growth at high rates of return. When we think about Allovir's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

PRESIDENT Since

Tsuyoshi TomitaTerumo Corp ADR
2018
Daniel RyanAlexandria Real Estate
2018
Paul HolbrookTerumo Corp ADR
N/A
Peter VolkersColoplast As B
N/A
Nicolai AndersenColoplast As B
N/A
Yoshiaki AkaikeTerumo Corp ADR
2016
Kyo NishikawaTerumo Corp ADR
2018
Charles BodnerBecton Dickinson And
2019
Paul MarcunColoplast As B
2019
Sara MomperHelmerich Payne
2020
Hiroshi NagumoTerumo Corp ADR
2012
Juichi TakeuchiTerumo Corp ADR
2018
Alain MorvanColoplast As B
N/A
David HickeyBecton Dickinson And
2021
Jeffrey ShermanBecton Dickinson And
2006
Wade ClarkHelmerich Payne
2017
Oliver JohansenColoplast As B
N/A
Masataka HaraguchiTerumo Corp ADR
2018
Gordon HelmHelmerich Payne
2018
Andrew RobinsonColoplast As B
2018
Hikaru SamejimaTerumo Corp ADR
2018
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. Allovir (ALVR) is traded on NASDAQ Exchange in USA and employs 110 people.

Allovir Leadership Team

Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
Doron Inbar, Non-Executive Independent Director
Raphael Amit, External Director
Zeev Farkash, Executive Vice President - Sales
Assaf Katan, Acting President and CEO
Moshe Fourier, Executive Vice President-R&D
Tali Aben, Non-Executive Independent Director
Mati Wax, CTO
Avi Stern, CFO
Amnon Yacoby, Independent Chairman of the Board
Nir Golan, Executive Vice President
Ziv Eizenberg, Executive Vice President-Human Resources
Leor Porat, Executive Vice President General Counsel

Allovir Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Allovir without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Tickers Now

   

Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allovir

+0.81DISWalt Disney Fiscal Year End 9th of November 2022 PairCorr

Moving against Allovir

-0.86JNJJohnson Johnson TrendingPairCorr
-0.63MRKMerck Company TrendingPairCorr
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.